イタリアでの肺癌治療に最適なクリニックと費用をご発見ください2026

Italy offers world-class lung cancer treatment at specialized IRCCS-accredited research hospitals in Milan and Rome. Leading centers like San Raffaele and the European Institute of Oncology provide multidisciplinary care. They utilize advanced robotic thoracic surgery and high-precision radiotherapy to treat complex pulmonary tumors.

• Hospital accreditation: San Raffaele holds IRCCS status from the Italian Ministry of Health.
• Surgical expertise: Dr. Giampiero Negri specializes in mini-invasive thoracic surgery for lung diseases.
• Radiation technology: Dr. Nadia Di Muzio utilizes high-precision hypofraction methods for oncological radiotherapy.
• Patient volume: San Raffaele performs over 52,000 operations annually across 18 specialized departments.

Bookimed Expert Insight: Italian IRCCS-accredited centers are unique because they legally must combine clinical care with research. This ensures patients get access to experimental protocols before they go mainstream. For example, San Raffaele was the first to implement specific stem cell therapies. This integration often leads to higher success rates in rare or resistant lung cancer cases.

Patient Consensus: Patients note that major tumor institutes in Milan and Rome offer exceptional expertise. Many recommend securing an EU health card early to help manage the logistics of decentralized care.

Italian oncology centers utilize robotic systems, high-precision radiation, and molecular therapies to treat lung cancer. Facilities like San Raffaele in Milan employ the da Vinci Xi robotic system for minimally invasive thoracic surgery. This approach reduces recovery times and improves surgical precision for complex lung resections.

• Robotic surgery: The da Vinci Xi system enables precise lobectomies through small incisions.
• Advanced radiotherapy: Tomotherapy and CyberKnife systems deliver high-dose radiation while sparing healthy tissue.
• Targeted therapy: Molecular profiling identifies specific genetic mutations for personalized drug treatments.
• Immunotherapy: PD-L1 testing guides the use of checkpoint inhibitors like Keytruda (Pembrolizumab).

Bookimed Expert Insight: While many countries offer standard radiation, Italian research hospitals like San Raffaele integrate Tomotherapy with high-precision hypofraction methods. Professor Nadia Di Muzio coordinates specialized protocols that deliver more intense radiation in fewer sessions. This combination is particularly effective for patients requiring both surgical and radiological interventions in a single treatment plan.

Patient Consensus: Patients often choose clinics in Northern Italy to access proton therapy and robotic surgery faster than through public waitlists. Many note that advanced molecular testing is the key first step to qualifying for the latest targeted therapy trials.

Immunotherapy and targeted therapies are widely available for lung cancer in Italy. These treatments are standard for non-small cell lung cancer (NSCLC). Public hospitals and specialized oncology centers provide them through the national health system. Access follows approval by the Italian Medicines Agency.

• Standard therapies: Drugs like pembrolizumab and nivolumab are common first-line treatments.
• Targeted options: Treatments target specific mutations including EGFR, ALK, and ROS1.
• Regional access: Northern regions like Lombardy often provide faster clinical protocol implementation.
• Specialized facilities: Research hospitals like San Raffaele in Milan provide advanced oncology care.

Bookimed Expert Insight: Expert centers in Milan and northern Italy handle high patient volumes. San Raffaele alone performs over 52,000 operations annually across all departments. This high surgical and clinical volume often correlates with faster access to molecular testing. Patients can benefit from integrated research and clinical practice at these major institutions.

Patient Consensus: Patients note that getting molecular testing early is vital for unlocking targeted options. While coverage is available nationwide, many share that traveling to northern oncology centers often reduces waiting times.

The 5-year survival rate for lung cancer in Italy is approximately 16% for men and 23% for women. Early diagnosis drastically improves outcomes. Stage I localized tumors show survival rates up to 90%. Advanced stage IV cases typically range between 6% and 10% survival.

• Gender differences: Women show higher survival due to biological factors and adenocarcinoma subtypes.
• Early stage: Localized tumors caught in Stage I reach 90% 5-year survival.
• Advanced stage: Metastatic Stage IV survival rates drop to approximately 6% to 10%.
• Regional variation: Northern and Central Italy report higher survival than Southern regions.

Bookimed Expert Insight: Clinical data from centers like San Raffaele in Milan confirms that high-volume surgical expertise impacts outcomes. Associate Professor Dr. Giampiero Negri specializes in mini-invasive thoracic surgery for lung diseases. This approach often leads to faster recovery times compared to traditional open chest surgeries. San Raffaele performs over 52,000 operations annually. This high patient volume is a key quality indicator for complex oncology cases.

Patient Consensus: Patients note that early genetic testing for mutations like EGFR is essential. Accessing targeted therapies like osimertinib in Northern Italian hospitals can significantly extend life expectancy.

International medical tourists face significant legal and clinical barriers when enrolling in lung cancer clinical trials in Italy. While major research centers like San Raffaele in Milan operate as global oncology hubs, most trials require Italian residency or an EU health card. Non-EU patients must navigate strict AIFA regulations and complex medical visa requirements.

• Residency requirement: Most Italian oncology trials prioritize Italian residents or EU health card holders.
• Regulatory oversight: The Italian Medicines Agency (AIFA) governs trials under strict EU Regulation 536/2014.
• Medical visa: Non-EU nationals require a Schengen Medical Visa with a formal hospital invitation.
• Language barrier: Informed consent processes often require proficiency in Italian for valid symptom reporting.

Bookimed Expert Insight: While Italy is a leader in thoracic research, its trial system is not traditionally designed for medical tourists. San Raffaele in Milan performs over 52,000 operations annually and holds prestigious IRCCS accreditation. However, patients without EU citizenship often find easier trial access in Germany or Switzerland. These neighboring countries frequently provide more robust infrastructure for international trial participants and English-speaking coordinators.

Patient Consensus: Patients note that paperwork for non-EU citizens can be nearly impossible to complete for clinical trials. Many suggest checking eligibility directly with trial sponsors before traveling to Milan or Rome to avoid rejection.

Lung cancer treatment in Italy relies on IRCCS-accredited research hospitals specialising in personalised medicine. Patients access molecular profiling for targeted therapies, immunotherapies like Keytruda, and robot-assisted thoracic surgery. High-precision radiotherapy systems, including CyberKnife and Tomotherapy, target tumours while sparing healthy tissue.

• Molecular profiling: Genetic screening identifies EGFR, ALK, and ROS1 mutations for targeted drug therapy.
• Robotic surgery: Specialists use the Da Vinci Robotic System for minimally invasive lung lobectomies.
• Precision radiation: Systems like CyberKnife and Tomotherapy deliver high-dose radiation to precise tumour areas.
• Systemic therapy: Specialised protocols include immunotherapy and chemotherapy based on specific PD-L1 biomarker levels.

Bookimed Expert Insight: Italian research hospitals like San Raffaele operate as IRCCS centres. These centres must legally combine clinical care with active research. Dr Nadia Di Muzio and her team have published over 200 studies. This ensures patients receive protocols backed by the latest trial data. This dual-focus environment often provides earlier access to emerging radiotherapy techniques like high-precision hypofractionation.

Patient Consensus: Patients emphasise that lung cancer treatment in Italy starts with detailed molecular testing. These results determine if immunotherapy or targeted drugs are suitable. Experience shows that private care often bypasses the longer wait times found in the public health system.

San Raffaele and the European Institute of Oncology (IEO) are Italy's premier centres for lung cancer treatment. These facilities specialise in robotic thoracic surgery and high-precision radiotherapy. They combine clinical excellence with research to handle complex oncology cases with high success rates.

• Specialised departments: San Raffaele performs over 52,000 operations annually across its major surgical units.
• Robotic surgery: Surgeons like Dr Giampiero Negri focus on minimally invasive techniques for pleural diseases.
• Radiotherapy: Prof Nadia Di Muzio leads departments using Tomotherapy and high-precision hypofractionated methods.
• National hubs: IRCCS-accredited centres in Milan and Rome lead international studies on innovative lung protocols.

Bookimed Expert Insight: While many patients focus on general oncology, the best outcomes in Italy often come from IRCCS-accredited research hospitals. These centres, including San Raffaele, receive specific government funding for research. This environment allows specialists like Prof Nadia Di Muzio to offer Tomotherapy and brachytherapy years before they become standard in smaller private clinics.

Patient Consensus: Patients in Italy value the multidisciplinary approach where thoracic surgeons and radiation oncologists collaborate on single cases. Many appreciate that these major Milanese hospitals provide technology like the Da Vinci system alongside research-driven care.

International patients can participate in Italian lung cancer clinical trials. This is common at IRCCS-accredited research hospitals. Eligibility depends on specific trial protocols and histopathological diagnosis. Patients must also be able to travel for frequent monitoring. Many Phase I–III trials for non-small-cell lung cancer provide experimental drugs for free.

• Research accreditation: IRCCS certification identifies Italian hospitals that combine clinical care with medical research.
• Specialised centres: San Raffaele in Milan is one of Europe's largest research hospitals for oncology.
• Eligibility criteria: Patients typically need a confirmed diagnosis and must be at least 18 years old.
• Language requirements: Many trials require the ability to understand Italian for informed consent.
• Clinical leadership: Specialists like Prof. Nadia Di Muzio at San Raffaele lead departments focused on research.

Bookimed Expert Insight: Italy is a hub for oncology research. However, clinical eligibility often requires having a local oncologist. Data shows that IRCCS-accredited clinics like San Donato and San Raffaele see over 300,000 patients annually. These centres merge research with daily practice. Patients should confirm if trial sponsors accept diagnostic results from Australian laboratories.

Patient Consensus: Patients say it is vital to check if Australian pathology slides are accepted before travelling. They also recommend verifying if an English-speaking coordinator can assist with monitoring after returning home.